Featured Research

from universities, journals, and other organizations

Putting Lupus in permanent remission

Date:
November 11, 2013
Source:
Northwestern University
Summary:
Scientists have successfully tested a nontoxic therapy that suppresses Lupus in blood samples of people with the autoimmune disease.

Northwestern Medicineฎ scientists have successfully tested a nontoxic therapy that suppresses Lupus in blood samples of people with the autoimmune disease.

This is a positive step toward one day developing a vaccine-like therapy that could keep Lupus in remission in the human body without the use of toxic drugs.

The study was published online in Clinical Immunology, the journal of the Federation of Clinical Immunology Societies.

Lupus is a chronic, autoimmune disease that causes the body to create autoantibodies that attack and destroy healthy tissue and cause inflammation, pain and damage in various vital organs of the body. According to the Lupus Foundation of America, it is believed that 5 million people throughout the world have a form of lupus.

In past studies, Northwestern scientists showed that a nontoxic therapy (which uses synthetic peptides -- small bits of protein -- to generate special regulatory T cells) blocks lupus in mice that are prone to the disease.

For this new study, 30 lupus patients (10 active and 20 in remission) and 15 healthy patients were enrolled and their blood samples were cultured with low doses of the special peptides.

"We found that the peptides could not only generate regulatory T cells, but also that they block and reduce autoantibody production to almost baseline levels in the blood cultures from people with active Lupus," said Syamal Datta, M.D., senior author of the study. "This approach shows that the peptides have the potential to work like a vaccine in the human body, to boost the regulatory immune system of those with Lupus, fight autoimmune antibodies and keep the disease in remission."

Datta is a professor of medicine-rheumatology and microbiology-immunology at Northwestern University Feinberg School of Medicine.

Steroids and Cytoxan are the most common therapies used to help treat people with lupus and even at very low doses the side effects of the drugs are toxic. Much like chemotherapy, lupus drugs can compromise fertility and weaken the immune system, making it difficult for patients to have children and leaving their bodies susceptible to infections. Also, such toxic drugs cannot be given indefinitely.

"This nontoxic therapy works like a vaccine in that the peptides are recognized by the bodies of almost every individual we have seen," Datta said. "It can be given to both subjects with and without lupus and boost their regulatory response with no side effects. We don't have to design something specifically for an unusual person. It works in everybody."

This study relates to Datta's more than 27 years of research in the lupus field focused on the cloning of the T cells that drive lupus autoimmunity. Datta's team identified the peptides used in this study in 1996, and Northwestern University holds the intellectual rights to these patented discoveries but has published the sequences of the peptides for open access to everyone.

"It is our hope that the next step is a phase one clinical trial in humans to show the efficacy of the peptide therapy in patients with lupus," Datta said. "The key is to find an industry partner that has experience in these kind of therapies so that we can move forward."


Story Source:

The above story is based on materials provided by Northwestern University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Li Zhang, Anne M. Bertucci, Rosalind Ramsey-Goldman, Elizabeth Randall Harsha-Strong, Richard K. Burt, Syamal K. Datta. Major pathogenic steps in human lupus can be effectively suppressed by nucleosomal histone peptide epitope-induced regulatory immunity. Clinical Immunology, 2013; 149 (3): 365 DOI: 10.1016/j.clim.2013.08.008

Cite This Page:

Northwestern University. "Putting Lupus in permanent remission." ScienceDaily. ScienceDaily, 11 November 2013. <www.sciencedaily.com/releases/2013/11/131111161512.htm>.
Northwestern University. (2013, November 11). Putting Lupus in permanent remission. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/11/131111161512.htm
Northwestern University. "Putting Lupus in permanent remission." ScienceDaily. www.sciencedaily.com/releases/2013/11/131111161512.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins